Human Immunodeficiency Virus-Associated Dementia: Clinical Aspects, Biology, and Treatment

Anita Venkataramana, Ned Sacktor

Research output: Contribution to journalArticle

Abstract

HIV-D in the era of HAART has a decreased incidence but a stable prevalence. CNS infection itself appears to be attenuated with a greater frequency of patients with milder forms of cognitive impairment, less correlation with CSF HIV RNA levels, and decreased markers of CNS inflammation. Surrogate markers of HIV-D from the pre-HAART era need to be re-evaluated in patients on HAART. As patients with HIV infection enter their 5th and 6th decades of life, new surrogate markers such as vascular and neurodegenerative disease markers need to be evaluated further to help differentiate between HIV-associated cognitive impairment and impairment due to co-morbid disease such as cerebrovascular disease or Alzheimer's disease. Therapies including both antiretroviral drugs and adjunctive therapies need to be examined further to improve treatment in patients with progressive HIV-associated cognitive impairment.

Original languageEnglish (US)
Pages (from-to)799-806
Number of pages8
JournalHandbook of Clinical Neurology
Volume89
DOIs
StatePublished - 2008

Fingerprint

Dementia
HIV
Highly Active Antiretroviral Therapy
Biomarkers
Therapeutics
Cerebrovascular Disorders
Vascular Diseases
Neurodegenerative Diseases
HIV Infections
Alzheimer Disease
RNA
Inflammation
Drug Therapy
Incidence
Infection
Cognitive Dysfunction

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Human Immunodeficiency Virus-Associated Dementia : Clinical Aspects, Biology, and Treatment. / Venkataramana, Anita; Sacktor, Ned.

In: Handbook of Clinical Neurology, Vol. 89, 2008, p. 799-806.

Research output: Contribution to journalArticle

@article{e896f31e237943e49a0d87beb70847fc,
title = "Human Immunodeficiency Virus-Associated Dementia: Clinical Aspects, Biology, and Treatment",
abstract = "HIV-D in the era of HAART has a decreased incidence but a stable prevalence. CNS infection itself appears to be attenuated with a greater frequency of patients with milder forms of cognitive impairment, less correlation with CSF HIV RNA levels, and decreased markers of CNS inflammation. Surrogate markers of HIV-D from the pre-HAART era need to be re-evaluated in patients on HAART. As patients with HIV infection enter their 5th and 6th decades of life, new surrogate markers such as vascular and neurodegenerative disease markers need to be evaluated further to help differentiate between HIV-associated cognitive impairment and impairment due to co-morbid disease such as cerebrovascular disease or Alzheimer's disease. Therapies including both antiretroviral drugs and adjunctive therapies need to be examined further to improve treatment in patients with progressive HIV-associated cognitive impairment.",
author = "Anita Venkataramana and Ned Sacktor",
year = "2008",
doi = "10.1016/S0072-9752(07)01269-9",
language = "English (US)",
volume = "89",
pages = "799--806",
journal = "Handbook of Clinical Neurology",
issn = "0072-9752",
publisher = "Elsevier",

}

TY - JOUR

T1 - Human Immunodeficiency Virus-Associated Dementia

T2 - Clinical Aspects, Biology, and Treatment

AU - Venkataramana, Anita

AU - Sacktor, Ned

PY - 2008

Y1 - 2008

N2 - HIV-D in the era of HAART has a decreased incidence but a stable prevalence. CNS infection itself appears to be attenuated with a greater frequency of patients with milder forms of cognitive impairment, less correlation with CSF HIV RNA levels, and decreased markers of CNS inflammation. Surrogate markers of HIV-D from the pre-HAART era need to be re-evaluated in patients on HAART. As patients with HIV infection enter their 5th and 6th decades of life, new surrogate markers such as vascular and neurodegenerative disease markers need to be evaluated further to help differentiate between HIV-associated cognitive impairment and impairment due to co-morbid disease such as cerebrovascular disease or Alzheimer's disease. Therapies including both antiretroviral drugs and adjunctive therapies need to be examined further to improve treatment in patients with progressive HIV-associated cognitive impairment.

AB - HIV-D in the era of HAART has a decreased incidence but a stable prevalence. CNS infection itself appears to be attenuated with a greater frequency of patients with milder forms of cognitive impairment, less correlation with CSF HIV RNA levels, and decreased markers of CNS inflammation. Surrogate markers of HIV-D from the pre-HAART era need to be re-evaluated in patients on HAART. As patients with HIV infection enter their 5th and 6th decades of life, new surrogate markers such as vascular and neurodegenerative disease markers need to be evaluated further to help differentiate between HIV-associated cognitive impairment and impairment due to co-morbid disease such as cerebrovascular disease or Alzheimer's disease. Therapies including both antiretroviral drugs and adjunctive therapies need to be examined further to improve treatment in patients with progressive HIV-associated cognitive impairment.

UR - http://www.scopus.com/inward/record.url?scp=66049140792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66049140792&partnerID=8YFLogxK

U2 - 10.1016/S0072-9752(07)01269-9

DO - 10.1016/S0072-9752(07)01269-9

M3 - Article

C2 - 18631795

AN - SCOPUS:66049140792

VL - 89

SP - 799

EP - 806

JO - Handbook of Clinical Neurology

JF - Handbook of Clinical Neurology

SN - 0072-9752

ER -